Targeting mTOR with MLN0128 Overcomes Rapamycin and Chemoresistant Primary Effusion Lymphoma

Primary effusion lymphoma (PEL) is caused by Kaposi’s sarcoma-associated herpesvirus (KSHV). PEL has a highly active mTOR pathway, which makes mTOR a potential therapeutic target. MLN0128 is an ATP-competitive inhibitor of mTOR that has entered clinical trials for solid tumors. Our results demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales: Caro-Vegas, Carolina, Bailey, Aubrey, Bigi, Rachele, Damania, Blossom, Dittmer, Dirk P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381283/
https://www.ncbi.nlm.nih.gov/pubmed/30782662
http://dx.doi.org/10.1128/mBio.02871-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381283/
https://www.ncbi.nlm.nih.gov/pubmed/30782662
http://dx.doi.org/10.1128/mBio.02871-18

Ejemplares similares